Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Invivyd (Nasdaq: IVVD) granted stock options as employment inducements under Nasdaq Listing Rule 5635(c)(4).

Rhea-AI Summary

Invivyd (Nasdaq: IVVD) granted stock options as employment inducements under Nasdaq Listing Rule 5635(c)(4). On July 1, 2026, 14 newly hired non-executive employees received options for an aggregate 493,000 common shares at an exercise price of $0.8544 per share.

Each option vests over four years, with 25% vesting on the first anniversary of the employee’s start date and the remainder vesting in equal monthly installments, subject to continuous service. The options have a 10-year term and were issued under the 2026 Inducement Plan.

Positive

• 493,000 stock options granted to support hiring of 14 employees
• Exercise price set at $0.8544, matching market closing price on grant date
• Four-year vesting schedule designed to promote employee retention

Negative

• Potential future dilution from 493,000 additional option-based shares

Argus Jul 2 session

+4.61% close to close Open Argus

Details

News Market Reaction – IVVD

In the Jul 2 session, IVVD gained 4.61%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

Invivyd’s grant of 493,000 inducement option shares at $0.8544 extends a pattern seen with June’s 51...

Analysis

Invivyd’s grant of 493,000 inducement option shares at $0.8544 extends a pattern seen with June’s 513,500-share awards, signaling ongoing hiring while modestly increasing potential dilution; investors may watch future equity usage alongside financing needs and trial progress.

Key Figures

New hire option recipients: 14 employees Inducement option shares: 493,000 shares Exercise price: $0.8544 per share +3 more

New hire option recipients

14 employees

Non-executive employees receiving inducement grants on July 1, 2026

Inducement option shares

493,000 shares

Aggregate options granted to new hires as inducement awards

Exercise price

$0.8544 per share

Option strike equal to July 1, 2026 closing price

Vesting schedule

4 years

Options vest over four years, subject to continuous service

Cliff vesting portion

25%

Vests on first anniversary of employee start date

Option term

10 years

Contractual life of inducement stock options

Historical Context

5 past events · Latest: Jun 16

5 events

1. Jun 16

   Phase 3 enrollment

   24h Move

   +2.7%

   Completed enrollment in Phase 3 LIBERTY trial for VYD2311 versus mRNA vaccine.

2. Jun 09

   Phase 3 dosing start

   24h Move

   -3.8%

   First participants dosed in LIBERTY Phase 3 trial evaluating VYD2311 and mRNA vaccine.

3. Jun 03

   Inducement option grants

   24h Move

   -3.5%

   Granted options for 513,500 shares to new employees under 2026 Inducement Plan.

4. Jun 01

   Pivotal trial enrollment

   24h Move

   +7.0%

   Completed enrollment in upsized Phase 3 DECLARATION trial of VYD2311 for COVID prevention.

5. May 27

   Investor conferences

   24h Move

   +2.7%

   Announced participation in multiple June 2026 healthcare and infectious disease investor events.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

nasdaq listing rule 5635(c)(4), inducement plan

2 terms

nasdaq listing rule 5635(c)(4) regulatory

"The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

inducement plan financial

"pursuant to the Invivyd, Inc. 2026 Inducement Plan"

An inducement plan is a program a company creates to encourage employees or new hires to stay or join by offering special benefits or rewards. It’s like a company giving extra bonuses or perks to persuade someone to choose their job over others, helping the company attract and keep talented workers.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW HAVEN, Conn., July 02, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that on July 1, 2026, Invivyd granted 14 newly hired non-executive employees options to purchase an aggregate of 493,000 shares of its common stock, each as a material inducement for each employee’s entry into employment with Invivyd. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and pursuant to the Invivyd, Inc. 2026 Inducement Plan.

The options have a per share exercise price of $0.8544, representing the closing price of Invivyd’s common stock on the grant date. Each option vests over four years, with 25% of the shares subject to such option vesting on the first anniversary of the employee’s start date and the remaining shares vesting in equal monthly installments thereafter, in each case, subject to the employee’s continuous service with Invivyd. The options have a 10-year term and are subject to the terms of the Invivyd, Inc. 2026 Inducement Plan.

About Invivyd  

Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. Invivyd deploys a proprietary integrated technology platform unique in the industry designed to assess, monitor, develop, and adapt to create best in class antibodies. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for a monoclonal antibody (mAb) in its pipeline of innovative antibody candidates. Visit https://invivyd.com/ to learn more. 

This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release.

Contacts:

Media Relations
(781) 208-0160
media@invivyd.com

Investor Relations
(781) 208-1747
investors@invivyd.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What inducement stock options did Invivyd (IVVD) grant on July 1, 2026?

Invivyd granted options to purchase an aggregate 493,000 common shares to 14 newly hired non-executive employees. According to Invivyd, these options were issued as material inducements for employment under its 2026 Inducement Plan and Nasdaq Listing Rule 5635(c)(4).

What is the exercise price of the new Invivyd (IVVD) inducement options?

The inducement options have an exercise price of $0.8544 per share. According to Invivyd, this price equals the closing price of its common stock on the July 1, 2026 grant date, aligning option pricing with contemporaneous market value.

How do the Invivyd (IVVD) inducement stock options vest for new employees?

The options vest over four years, with 25% vesting on the first anniversary of each employee’s start date. According to Invivyd, the remaining shares vest in equal monthly installments thereafter, subject to continuous service with the company.

What is the term of the Invivyd (IVVD) inducement stock options granted in 2026?

Each inducement option has a 10-year term from the grant date. According to Invivyd, these options remain exercisable during this period, subject to vesting, continuous service conditions, and the terms of the 2026 Inducement Plan.

Why did Invivyd (IVVD) use Nasdaq Listing Rule 5635(c)(4) for these option grants?

Invivyd used Nasdaq Listing Rule 5635(c)(4) to grant options as material inducements to new hires. According to Invivyd, the 493,000-share option awards were made under its 2026 Inducement Plan specifically for newly hired non-executive employees.

How might the 493,000 Invivyd (IVVD) inducement options affect existing shareholders?

If exercised, the 493,000 inducement options would increase the company’s outstanding shares. According to Invivyd’s grant details, this potential expansion of the share count could create future dilution relative to current shareholders’ ownership percentages.